Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2025 04:26 ET | Source: Janssen Cilag International NV

European Commission approves TREMFYA® (guselkumab), the first dual-acting IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn’s disease

TREMFYA® (guselkumab) induction therapy administered either intravenously (GALAXI 2 and 3) or subcutaneously (GRAVITI) achieved the co-primary endpoints of clinical remissiona and endoscopic responseb...
May 01, 2025 08:30 ET | Source: Palisade Bio, Inc.

Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

Carlsbad, CA, May 01, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and...
April 25, 2025 03:00 ET | Source: Janssen Cilag International NV

TREMFYA® (guselkumab) receives European Commission approval for adults with moderately to severely active ulcerative colitis, strengthening Johnson & Johnson’s leadership in inflammatory bowel disease

The firsta approved fully-human, dual-acting interleukin-23 (IL-23) inhibitor in moderately to severely active ulcerative colitis,1,2,3,4,5 guselkumab showed statistically higher rates of endoscopic...
April 15, 2025 07:30 ET | Source: Attovia Therapeutics, Inc.

Attovia Therapeutics Announces $90 Million Series C Financing to Advance ATTOBODY-based Programs through Clinical Proof of Concept

Series C round led by Deep Track Capital with participation from additional new and existing investors Financing will fund early-to-mid-stage clinical studies for ATTO-1310 in chronic pruritus and...
April 02, 2025 09:32 ET | Source: Research and Markets

Inflammatory Bowel Disease Treatment Market Forecast Report 2025-2033 Featuring Abbott Laboratories, AbbVie, Allergan Therapeutics, Bausch, Bristol-Myers Squibb, Johnson & Johnson, Novartis and Pfizer

Dublin, April 02, 2025 (GLOBE NEWSWIRE) -- The "Inflammatory Bowel Disease Treatment Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" report has been added to ...
April 02, 2025 08:05 ET | Source: Organovo, Inc.

Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements

SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment...
March 28, 2025 07:20 ET | Source: Janssen Cilag International NV

TREMFYA® (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn’s Disease

Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 1,2,3 Beerse, Belgium (28 March 2025) – Johnson & Johnson today announced that the...
March 27, 2025 08:05 ET | Source: Organovo, Inc.

Organovo Provides Business Update

SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment...
March 25, 2025 11:25 ET | Source: Organovo, Inc.

Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company

SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment...
March 19, 2025 08:05 ET | Source: Organovo, Inc.

Organovo Announces Reverse Stock Split

SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel...

Next Page keyboard_arrow_right